Sirtex Medical Limited operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sirtex Medical Limited with three other
miscellaneous service companies in Australasia:
sales of 17.64 million Australian Dollars [US$13.91 million]
of which 77%
was Bronchitol and Aridol),
Xrf Scientific Ltd
(21.54 million Australian Dollars [US$16.99 million]
of which 40%
was Precious Metals), and
(18.61 million Australian Dollars [US$14.67 million]
of which 88%
was Drug discovery and development).
During the year ended June of 2017, sales at
Sirtex Medical Limited were A$234.28 million (US$184.76 million).
a very small
increase of 0.8%
versus 2016, when the company's sales were A$232.49 million.
This was the fifth consecutive year of sales increases at Sirtex Medical Limited
(and since 2012, sales have increased a total of 184%).
Sales of Emea saw an increase
that was more than double the company's growth rate: sales were up
419.7% in 2017, from
A$38.93 million to A$202.30 million.
Sirtex Medical Limited also saw significant increases in sales in
Americas (up 1.0% to A$201.03 million)
Unallocated (up 18.7% to A$2.65 million)
Not all segments of Sirtex Medical Limited experienced an increase in sales in 2017:
sales of Asia Pacific fell 89.6% to A$17.91 million.